In cancer models, BET(bromodomain and extra-terminal motif) inhibitors have been shown to positively impact CD8+T cells by directly inhibiting BATF, thereby enhancing the persistence of stem-like memory CD8+T cells [120]. This evidence concerns the gene CD8A and cancer.